BR112018074056A2 - composições e métodos relacionados a construtos de fc manipulados - Google Patents

composições e métodos relacionados a construtos de fc manipulados

Info

Publication number
BR112018074056A2
BR112018074056A2 BR112018074056-0A BR112018074056A BR112018074056A2 BR 112018074056 A2 BR112018074056 A2 BR 112018074056A2 BR 112018074056 A BR112018074056 A BR 112018074056A BR 112018074056 A2 BR112018074056 A2 BR 112018074056A2
Authority
BR
Brazil
Prior art keywords
constructs
manipulated
compositions
methods related
methods
Prior art date
Application number
BR112018074056-0A
Other languages
English (en)
Portuguese (pt)
Inventor
J. Bosques Carlos
C. Lansing Jonathan
Ortiz Daniel
Rutitzky Laura
J. Washburn Nathaniel
Original Assignee
Momenta Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals, Inc. filed Critical Momenta Pharmaceuticals, Inc.
Publication of BR112018074056A2 publication Critical patent/BR112018074056A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
BR112018074056-0A 2016-05-23 2017-05-23 composições e métodos relacionados a construtos de fc manipulados BR112018074056A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662340322P 2016-05-23 2016-05-23
US62/340,322 2016-05-23
US201762443451P 2017-01-06 2017-01-06
US62/443,451 2017-01-06
PCT/US2017/034084 WO2017205434A1 (en) 2016-05-23 2017-05-23 Compositions and methods related to engineered fc constructs

Publications (1)

Publication Number Publication Date
BR112018074056A2 true BR112018074056A2 (pt) 2019-03-06

Family

ID=60412547

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112018074056-0A BR112018074056A2 (pt) 2016-05-23 2017-05-23 composições e métodos relacionados a construtos de fc manipulados
BR112018074032-2A BR112018074032A2 (pt) 2016-05-23 2017-05-23 composições e métodos relacionados a construtos de fc manipulados

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112018074032-2A BR112018074032A2 (pt) 2016-05-23 2017-05-23 composições e métodos relacionados a construtos de fc manipulados

Country Status (14)

Country Link
US (4) US11155640B2 (https=)
EP (2) EP3484514B1 (https=)
JP (5) JP7045333B6 (https=)
KR (3) KR102590061B1 (https=)
CN (4) CN118206639A (https=)
AU (2) AU2017272109B2 (https=)
BR (2) BR112018074056A2 (https=)
CA (2) CA3025310A1 (https=)
DK (1) DK3484514T3 (https=)
ES (1) ES2973251T3 (https=)
IL (3) IL263211B2 (https=)
PL (1) PL3484514T3 (https=)
SG (3) SG11201810465RA (https=)
WO (2) WO2017205436A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4299595A3 (en) 2014-05-02 2024-03-13 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
EP3423572B1 (en) 2016-03-02 2023-11-29 Momenta Pharmaceuticals, Inc. Methods related to engineered fc constructs
DK3484514T3 (da) * 2016-05-23 2024-01-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
JP7146771B2 (ja) * 2017-01-06 2022-10-04 モメンタ ファーマシューティカルズ インコーポレイテッド 操作されたＦｃコンストラクトに関する組成物及び方法
US20210284717A1 (en) * 2018-07-11 2021-09-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
CN113382749A (zh) * 2018-07-11 2021-09-10 动量制药公司 与工程化Fc-抗原结合结构域构建体有关的组合物和方法
CA3106212A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
KR20210044783A (ko) * 2018-07-11 2021-04-23 모멘타 파머슈티컬스 인코포레이티드 CTLA-4 표적화 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법
US20210238310A1 (en) * 2018-07-11 2021-08-05 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
MX2021000307A (es) * 2018-07-11 2021-09-08 Momenta Pharmaceuticals Inc Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc dirigidos a cd38 diseñados por ingeniería genética.
CA3105985A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4
JP2021530989A (ja) * 2018-07-11 2021-11-18 モメンタ ファーマシューティカルズ インコーポレイテッド ＰＤ−Ｌ１を標的とした改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法
KR102661494B1 (ko) 2019-03-08 2024-04-29 에이치엘만도 주식회사 랙구동형 동력 보조 조향장치
AU2020344164A1 (en) 2019-09-13 2022-04-14 CSL Behring Lengnau AG Recombinant IgG Fc multimers for the treatment of immune complex-mediated kidney disorders
BR112022010096A2 (pt) * 2019-12-06 2022-09-06 CSL Behring Lengnau AG Composições estáveis de multímeros fc
CN111808170A (zh) * 2020-06-29 2020-10-23 江苏为真生物医药技术股份有限公司 多肽、hla-dr蛋白及其制备方法和应用
EP4255933A4 (en) * 2020-12-07 2025-07-23 Invetx Inc COMPOSITIONS FOR INCREASING THE HALF-LIFE OF A THERAPEUTIC AGENT IN LIVESTOCK ANIMALS AND METHODS OF USE
WO2024206820A1 (en) * 2023-03-30 2024-10-03 Dna Twopointo, Inc. Fc engineering for heterodimeric antibody format

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2556219B1 (fr) 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
US5426641A (en) 1994-01-28 1995-06-20 Bell Communications Research, Inc. Adaptive class AB amplifier for TDMA wireless communications systems
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2257861A1 (en) 1996-06-14 1997-12-18 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US20090074839A1 (en) 1997-01-22 2009-03-19 Marton Milankovits Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
PE20081140A1 (es) * 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
BRPI0620639A2 (pt) 2006-12-21 2011-11-22 Micromet Ag anticorpos de cadeia simples biespecìficos e composição farmacêutica compreendendo os mesmos
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
PL2185589T3 (pl) 2007-06-01 2016-09-30 Środki wiążące receptor regionu stałego Fc immunoglobuliny
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
WO2009123894A2 (en) 2008-04-02 2009-10-08 Macrogenics, Inc. Her2/neu-specific antibodies and methods of using same
EP2341929B1 (en) 2008-10-06 2017-01-25 University Of Chicago Compositions and methods related to bacterial emp proteins
WO2010065578A2 (en) 2008-12-04 2010-06-10 Leukosight Inc. POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
US10865233B2 (en) 2008-12-18 2020-12-15 Dana-Farber Cancer Institute, Inc. NKG2D-fc for immunotherapy
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
EP2432451A2 (en) 2009-05-20 2012-03-28 Children's Medical Center Corporation Compositions for the treatment of metastatic cancer and methods of use thereof
EP2432803A2 (en) 2009-05-20 2012-03-28 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
CN102549016B (zh) * 2009-06-30 2015-05-06 研究发展基金会 免疫球蛋白fc多肽
EP2478013B1 (en) 2009-09-16 2018-10-24 F.Hoffmann-La Roche Ag Coiled coil and/or tether containing protein complexes and uses thereof
JP5898082B2 (ja) 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
MX340971B (es) 2009-11-23 2016-08-02 Amgen Inc * Fragmento cristalizable (fc) de anticuerpo monomerico.
GB0922209D0 (en) 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
EP2571992B1 (en) 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
TWI542597B (zh) 2010-07-28 2016-07-21 吉林尼克公司 產生依序多聚體化免疫球蛋白ｆｃ組合物之天然人類蛋白質片段之融合蛋白
JP2013537416A (ja) 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
ES2623912T3 (es) * 2010-12-23 2017-07-12 Janssen Biotech, Inc. Mutantes FC de anticuerpo activo resistente a proteasa
IN2013MN01438A (https=) 2011-03-17 2015-06-12 Univ Ramot
BR112013023918A2 (pt) 2011-03-25 2016-12-13 Glenmark Pharmaceuticals Sa imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural
BR112014010580B1 (pt) * 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
WO2013185113A1 (en) * 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
HK1209034A1 (en) 2012-06-21 2016-03-24 Indiana University Research And Technology Corporation Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
US9683044B2 (en) 2012-08-20 2017-06-20 Gliknik Inc. Molecules with antigen binding and polyvalent FC gamma receptor binding activity
BR112015008663B1 (pt) * 2012-10-17 2021-01-12 CSL Behring Lengnau AG Uso de uma quantidade eficaz de uma proteína polimérica compreendendo seis unidades demonômero de polipeptídeo
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
CN104558194B (zh) * 2013-10-17 2018-04-27 泰州迈博太科药业有限公司 一类抗CD20-Flex双功能融合蛋白、其制备方法及用途
EP3082847A1 (en) * 2013-12-20 2016-10-26 Indiana University Research and Technology Corporation Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides
RU2727639C2 (ru) 2014-01-15 2020-07-22 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
CN113248613B (zh) 2014-01-15 2024-08-23 豪夫迈·罗氏有限公司 具有修饰的FCRN结合性质的Fc区变体
CA2939201A1 (en) 2014-03-05 2015-09-11 Ucb Biopharma Sprl Multimeric fc proteins
MX2016010951A (es) 2014-03-05 2016-11-29 Ucb Biopharma Sprl Proteinas de fc multimericas.
CA2945882A1 (en) 2014-04-16 2015-10-22 Ucb Biopharma Sprl Multimeric fc proteins
EP4299595A3 (en) 2014-05-02 2024-03-13 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
EA035419B9 (ru) * 2014-05-29 2020-08-07 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы и способы их применения
EP3423572B1 (en) 2016-03-02 2023-11-29 Momenta Pharmaceuticals, Inc. Methods related to engineered fc constructs
DK3484514T3 (da) 2016-05-23 2024-01-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
JP7146771B2 (ja) * 2017-01-06 2022-10-04 モメンタ ファーマシューティカルズ インコーポレイテッド 操作されたＦｃコンストラクトに関する組成物及び方法

Also Published As

Publication number Publication date
CN109963869A (zh) 2019-07-02
AU2017272109B2 (en) 2024-07-25
JP2022068176A (ja) 2022-05-09
JP2019519528A (ja) 2019-07-11
AU2017272109A1 (en) 2019-01-17
IL309293A (en) 2024-02-01
ES2973251T3 (es) 2024-06-19
AU2017272111A1 (en) 2019-01-17
JP2019519527A (ja) 2019-07-11
JP7295301B2 (ja) 2023-06-20
SG11201810465RA (en) 2018-12-28
EP3464376A1 (en) 2019-04-10
WO2017205436A1 (en) 2017-11-30
CN118206639A (zh) 2024-06-18
WO2017205434A1 (en) 2017-11-30
SG11201810466PA (en) 2018-12-28
US11623964B2 (en) 2023-04-11
IL263211B2 (en) 2023-09-01
IL263213A (en) 2018-12-31
KR102462084B1 (ko) 2022-11-02
AU2017272111B2 (en) 2024-05-16
IL263211A (en) 2018-12-31
EP3464376A4 (en) 2020-03-18
KR20190021255A (ko) 2019-03-05
CA3025306A1 (en) 2017-11-30
CN109789203B (zh) 2022-08-05
KR20190026684A (ko) 2019-03-13
EP3484514B1 (en) 2023-12-06
CA3025310A1 (en) 2017-11-30
US12297291B2 (en) 2025-05-13
SG10202011624SA (en) 2021-01-28
JP7045333B6 (ja) 2022-05-06
PL3484514T3 (pl) 2024-04-29
IL263213B1 (en) 2024-01-01
EP3484514A4 (en) 2020-08-12
KR20220151025A (ko) 2022-11-11
JP2025026880A (ja) 2025-02-26
US20240067757A1 (en) 2024-02-29
US20210221917A1 (en) 2021-07-22
US11155640B2 (en) 2021-10-26
BR112018074032A2 (pt) 2019-02-26
IL263211B1 (en) 2023-05-01
JP2022095685A (ja) 2022-06-28
KR102635635B1 (ko) 2024-02-14
NZ749279A (en) 2025-08-29
DK3484514T3 (da) 2024-01-29
CN116063540A (zh) 2023-05-05
JP7045333B2 (ja) 2022-03-31
EP3484514A1 (en) 2019-05-22
US20220049019A1 (en) 2022-02-17
KR102590061B1 (ko) 2023-10-18
IL263213B2 (en) 2024-05-01
CN109789203A (zh) 2019-05-21
NZ749292A (en) 2025-08-29
US20190284305A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
BR112018074056A2 (pt) composições e métodos relacionados a construtos de fc manipulados
BR112018008901A8 (pt) formulações subcutâneas de anticorpos anti-cd 38 e seus usos
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
MX2022005202A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
EP4299595A3 (en) Compositions and methods related to engineered fc constructs
CO2020012347A2 (es) Anticuerpos anti-hla-g y usos de los mismos.
PT3436054T (pt) Composições de toxina clostridial não proteicas estabilizadas
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
DK3411404T3 (da) Psma- og cd3-bispecifikke t-celleinddragende antistofkonstruktioner
LT3443009T (lt) Anti-tim-3 antikūnai ir kompozicijos
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
EA201791485A1 (ru) Анти-cd47-антитела и их применения
BR112017001796A2 (pt) composições de flagelina e seus usos
MX384364B (es) Anticuerpos anti-pd-l1 y sus usos de diagnóstico.
IL263764A (en) Anti-cd19 antibody formulations
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
PH12020550930A1 (en) Human igg fc domain variants with improved effector function
BR112021011124A2 (pt) Anelossomos e métodos de uso
MX2017002469A (es) Composiciones de matrices extracelulares.
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
MX377774B (es) Formulaciones de proteinas.
BR112018009004A8 (pt) conjugados anti-cd3-folato e seus usos
EP3565588A4 (en) COMPOSITIONS AND METHODS RELATING TO MODIFIED FC CONSTRUCTIONS

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements